Cabergoline vs Trenbolone
FDA Approved vs Moderate Research
synergistic Researched · 95% Cabergoline is a dopamine agonist considered essential for prolactin management during trenbolone use. Trenbolone's progestogenic activity elevates prolactin levels, which can cause gynecomastia, lactation, sexual dysfunction, and mood disturbance. Typical dosing is 0.25-0.5 mg twice weekly, adjusted based on bloodwork. Prolactin should be confirmed elevated via blood test before initiating cabergoline -- prophylactic use without bloodwork confirmation is generally discouraged but having it on hand is considered mandatory.
Molecular Data
Cabergoline Trenbolone
Weight 451.60 Da 270.37 Da (base)
Half-life ~63-69 hours ~3 days (acetate)
Type Ergoline-derived dopamine D2 receptor agonist 19-nortestosterone derivative (C18H22O2), trienone steroid
Key Benefits
Cabergoline
01 Potent suppression of prolactin levels, often normalizing them within days
02 Prevents and reverses prolactin-related gynecomastia from 19-nor compounds
03 Restores sexual function impaired by hyperprolactinemia (libido, erectile function, orgasm)
04 Long half-life (63-69 hours) allows convenient twice-weekly dosing
05 Significantly better tolerated than bromocriptine with fewer gastrointestinal side effects
06 Effective at shrinking prolactin-secreting pituitary tumors
07 Low doses required for bodybuilding prolactin management (0.25-0.5mg twice weekly)
Trenbolone
01 Exceptional lean muscle mass accrual with minimal water retention due to non-aromatizing profile
02 Dramatic body recomposition capability -- simultaneous muscle gain and fat loss even in caloric deficit
03 Approximately five times the anabolic and androgenic potency of testosterone (500:500 ratio)
04 Powerful anti-catabolic effects through glucocorticoid receptor antagonism, protecting muscle during dieting
05 Significant increases in strength across all compound movements, often rapid in onset
06 Enhanced nutrient partitioning, directing calories toward lean tissue accretion over fat storage
07 Pronounced muscle hardness, density, and vascularity due to absence of estrogenic water retention
08 Increased IGF-1 production in muscle tissue, amplifying growth signaling pathways
Dosing Protocols
Cabergoline
0.25-0.5mg twice weekly (bodybuilding); 0.5-1mg twice weekly (medical) / Twice weekly
Trenbolone
200-400 mg/week / Every other day (acetate) or 2x per week (enanthate)
Recomposition - Moderate (Acetate) 200-300 mg/week (50-75 mg every other day) Every other day
Advanced Cutting (Acetate) 300-400 mg/week (75-100 mg every other day) Every other day
Lean Bulk (Enanthate) 200-400 mg/week 2x per week
Contest Preparation - Advanced 300-500 mg/week Every other day (acetate) or 2x per week (enanthate)
Side Effects
Cabergoline
Nausea (especially during initial doses; mitigated by taking with food)
Dizziness or lightheadedness
Headache
Nasal congestion or stuffiness
Fatigue or drowsiness
Orthostatic hypotension (feeling faint when standing up quickly)
Trenbolone
Insomnia and severely disrupted sleep architecture (one of the most universally reported side effects, affecting the majority of users)
Night sweats, often drenching, requiring sheet changes
Significantly reduced cardiovascular endurance and aerobic capacity
Increased aggression, irritability, and shortened temper
Anxiety and restlessness, particularly at higher doses
Tren cough: acute, intense coughing fit lasting 30-90 seconds immediately after injection, caused by a small amount of oil entering a blood vessel
Dark-colored urine (oxidized metabolites; not necessarily indicative of kidney damage but should be monitored)
Elevated body temperature and increased sweating throughout the day
Acne and oily skin, particularly on shoulders, back, and chest
Accelerated hair loss in those genetically predisposed to male pattern baldness
Profoundly suppressive of natural testosterone production (near-complete HPT axis shutdown)
Increased heart rate and elevated blood pressure
Contraindications
Known hypersensitivity to cabergoline or any ergot alkaloid
History of cardiac valvular disease or clinically significant valvular regurgitation
History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Uncontrolled hypertension
Concurrent use of dopamine antagonists (antipsychotics, antiemetics acting on D2 receptors)
Severe hepatic impairment (cabergoline is extensively metabolized by the liver)
First steroid cycle or limited anabolic steroid experience (trenbolone is strictly an advanced-only compound)
Pre-existing cardiovascular disease, cardiomyopathy, or significant cardiac risk factors
History of mental health conditions: anxiety disorders, depression, bipolar disorder, or psychotic episodes
Liver disease or significantly elevated liver enzymes
Kidney disease or impaired renal function
Uncontrolled hypertension
Polycythemia (hematocrit above 54% at baseline)
Prostate cancer or history of hormone-sensitive cancers
Active or recent substance abuse (trenbolone's psychological effects can exacerbate addictive behaviors)
Pregnancy or potential for pregnancy in female partners (extremely virilizing compound)
Research Evidence
Cabergoline Trenbolone
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest — January 2023
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.